Previous close | 0.5000 |
Open | 0.5200 |
Bid | 0.4500 |
Ask | 0.6500 |
Strike | 4.00 |
Expiry date | 2024-08-16 |
Day's range | 0.5200 - 0.5200 |
Contract range | N/A |
Volume | |
Open interest | 2 |
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., P
This month, we saw the MacroGenics, Inc. ( NASDAQ:MGNX ) up an impressive 37%. But that doesn't change the fact that...
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will parti